MedTrace Logo

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in the UK

NCT01263457 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 191

Last updated 2021-05-05

No results posted yet for this study

Summary

This is a National, Multicentre, Observational Registry to study Adherence and Long Term Outcomes of Therapy in paediatric subjects using Easypod™ electromechanical device for growth hormone treatment from hospital in the UK and to assess the level of adherence of subject receiving SAIZEN® via Easypod™.

Conditions

  • Growth Disorders

Interventions

DEVICE

Easypod

Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod

Sponsors & Collaborators

  • Merck Serono Limited, UK

    collaborator INDUSTRY

  • Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Medical Responsible · Merck Serono Limited, UK

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01263457 on ClinicalTrials.gov